9
Participants
Start Date
December 12, 2017
Primary Completion Date
November 4, 2021
Study Completion Date
May 23, 2024
Durvalumab
1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
Tremelimumab
75mg via IV infusion every 4 weeks
Thoracic Radiation
5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
lobectomy
patients may proceed to surgery post drug and radiation intervention for lung lobectomy
Standard of care adjuvant chemotherapy
patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
Johns Hopkins Bayview Medical Center, Baltimore
Princess Margaret Cancer Centre, Toronto
Collaborators (1)
AstraZeneca
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER